drugset / Trial / NCT00259935

A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors

NCT00259935

Phase 1 Completed 107 enrolled GlaxoSmithKline
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to determine the bioequivalence of the new oral capsule formulation to the currently used oral capsule formulation of topotecan.

Timeline

Start
2004-10-04
Primary completion
2007-07-05
Completion
2007-07-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Topotecan Small molecule 4 mg Oral